Skip to main content

Beckman's Q2 Sales Miss Target as Profits Fall 20 Percent

NEW YORK (GenomeWeb News) — Beckman Coulter today reported a slight decrease in second-quarter sales accompanied by a 19-percent drop in net income.
 
Total receipts for the three months ended June 30 declined to $616.3 million, from $618.8 in the same period last year. Beckman had initially forecast revenues to be between $620 million and $645 million, and the company blamed the lower-than-expected revenues on lagging sales in the Asian market.
 
Research and development costs rose 50 percent to $75 million from $50 million year over year.
 
Net income for the quarter dropped 19 percent to $44.6 million from $55.2 million in the prior-year period.
 
As of June 30, Beckman Coulter had $59.4 million in cash and cash equivalents.
 
Beckman CEO Scott Garrett said that  the "revenues in the Far East were disappointing due to a combination of factors” including slower-than-expected transition to a direct sales model in China and the fact that “hospitals are delaying purchases due to an expanding Chinese government review of overall hospital buying practices.”
 
Garrett said that Beckman expects to be “back on track with [its] double-digit growth trend” by the beginning of 2007.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.